Is Eris Lifesciences Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Eris Lifesciences Ltd (ERIS.NS) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Eris Lifesciences Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Eris Lifesciences Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Eris Lifesciences Ltd?

Muslim investors may consider investing in Eris Lifesciences Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Eris Lifesciences Ltd classified as HALAL?

Musaffa determines the Shariah status of Eris Lifesciences Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Eris Lifesciences Ltd updated?

The Shariah compliance status of Eris Lifesciences Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Eris Lifesciences Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Eris Lifesciences Ltd?

You can check the latest Shariah compliance status of Eris Lifesciences Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ERIS.NS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: February 16, 2026

Report Source: 2026 3rd Quarter Report

Eris Lifesciences Ltd. Stock Analysis ERIS.NS

India Health Care Small Cap Report: Q3, 2026

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat and currently employs 3,558 full-time employees. The company went IPO on 2017-06-29. The firm is engaged in the manufacture and marketing of pharmaceutical products. The firm has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The firm has a manufacturing plant located in Guwahati, Assam.

Key Statistics of Eris Lifesciences Ltd (ERIS.NS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹1,355.00₹1,410.00

Today's Open

₹1,369.60

Volume

181.98K

P/E Ratio (TTM)

54.14

52 Week Range

₹1,200.00₹1,910.00

Market Cap

187.59B

Avg. Volume

134.60K

Dividend Yield

Financial Metrics & Statements of Eris Lifesciences Ltd (ERIS.NS)

FAQ's for Eris Lifesciences Ltd (ERIS.NS)

According to Musaffa’s Shariah screening methodology, Eris Lifesciences Ltd (ERIS.NS) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.